Radar›Companies›Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 21
United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 21

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness
Readiness leaderPrelude Therapeutics · 42
Strongest available pathAquestive Therapeutics · +20.2%
Widest latest marginScynexis · -41.8%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1PRLD · Nasdaq

Prelude Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2016Philadelphia, Pennsylvania$437.3M market cap
View full Companies Radar profile
42Cautious
Snapshot price$5.49as of page date
Monthly-close return-82.4%five-year window
FY2025 revenue$0.01BPrelude Therapeutics Inc
Net margin-819.6%FY2025
P/E snapshot-7.3xone ratio, not a verdict
Prism attention10.6%share across these five
Filing track recordRevenue, USD billions
+73.4%
$0$0.0B$0.0B$0.0BFY2024: $0.007BFY2025: $0.012B20242025
FY2024–FY2025 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 73.4%
52-week position77% through range
$0.98$6.83
News mentions365
Community mentions4partial coverage
U.S.-scope patents311
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal44/100
Management stability90/100
Market position7/100
Capital-event signal50/100
Innovation pulse9/100
Management signal

No leadership-churn flag in the model; 5 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 5 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2SCYX · Nasdaq

Scynexis

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1999Jersey City, New Jersey$51.4M market cap
View full Companies Radar profile
42Cautious
Snapshot price$5.17as of page date
Monthly-close return-87.8%five-year window
FY2025 revenue$0.02BSCYNEXIS INC
Net margin-41.8%FY2025
P/E snapshot-2.2xone ratio, not a verdict
Prism attention21.7%share across these five
Filing track recordRevenue, USD billions
+56.5%
$0$0.0B$0.1B$0.1BFY2021: $0.013BFY2022: $0.005BFY2023: $0.140BFY2024: $0.004BFY2025: $0.021B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 11.8%
52-week position24% through range
$3.53$10.48
News mentions746
Community mentions60partial coverage
U.S.-scope patents323
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal39/100
Management stability90/100
Market position8/100
Capital-event signal60/100
Innovation pulse9/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 2 asset-acquisition events and 6 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 5 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3SNGX · Nasdaq

Soligenix

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1987Princeton, New Jersey$8.2M market cap
View full Companies Radar profile
42Cautious
Snapshot price$0.38as of page date
Monthly-close return-99.9%five-year window
FY2024 revenue$0.00BSOLIGENIX, INC.
Net margin-3815.1%FY2024
P/E snapshot-1.5xone ratio, not a verdict
Prism attention31.4%share across these five
Filing track recordRevenue, USD billions
-88.8%
$0$0.0B$0.0B$0.0BFY2020: $0.002BFY2021: $0.001BFY2022: $0.001BFY2023: $0.001BFY2024: $0.000B20202021202220232024
FY2020–FY2024 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2021, FY2022, FY2023, FY2024 · CAGR -42.1%
52-week position3% through range
$0.28$3.22
News mentions1.1K
Community mentions0partial coverage
U.S.-scope patents191
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal38/100
Management stability90/100
Market position7/100
Capital-event signal66/100
Innovation pulse5/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4AQST · Nasdaq

Aquestive Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2005Warren, New Jersey$657.7M market cap
View full Companies Radar profile
41Cautious
Snapshot price$5.24as of page date
Monthly-close return+20.2%five-year window
FY2025 revenue$0.04BAquestive Therapeutics, Inc.
Net margin-188.1%FY2025
P/E snapshot-9.2xone ratio, not a verdict
Prism attention23.3%share across these five
Filing track recordRevenue, USD billions
-12.4%
$0$0.0B$0.0B$0.1BFY2021: $0.051BFY2022: $0.048BFY2023: $0.051BFY2024: $0.058BFY2025: $0.045B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -3.2%
52-week position50% through range
$2.93$7.55
News mentions803
Community mentions0partial coverage
U.S.-scope patents213
Prism Insights

What sits behind the readiness signal

Observed risk 8/100higher means more observed risk
Earnings signal69/100
Management stability90/100
Market position0/100
Capital-event signal38/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5JANX · Nasdaq

Janux Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2017San Diego, California$1.15B market cap
View full Companies Radar profile
41Cautious
Snapshot price$18.89as of page date
Monthly-close return-12.7%five-year window
FY2025 revenue$0.01BJanux Therapeutics, Inc.
Net margin-1136.2%FY2025
P/E snapshot-7.2xone ratio, not a verdict
Prism attention13.0%share across these five
Filing track recordRevenue, USD billions
+175.0%
$0$0.0B$0.0B$0.0BFY2021: $0.004BFY2022: $0.009BFY2023: $0.008BFY2024: $0.011BFY2025: $0.010B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 28.8%
52-week position29% through range
$12.12$35.34
News mentions448
Community mentions6partial coverage
U.S.-scope patents170
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal38/100
Management stability90/100
Market position0/100
Capital-event signal71/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 2 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Aquestive Therapeutics
+20.2%
Janux Therapeutics
-12.7%
Prelude Therapeutics
-82.4%
Scynexis
-87.8%
Soligenix
-99.9%

Latest revenue

USD billions, official filing scope shown on each company card.

Aquestive Therapeutics
$0.04B
Scynexis
$0.02B
Prelude Therapeutics
$0.01B
Janux Therapeutics
$0.01B
Soligenix
$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Scynexis
-41.8%
Aquestive Therapeutics
-188.1%
Prelude Therapeutics
-819.6%
Janux Therapeutics
-1136.2%
Soligenix
-3815.1%

Prism news attention

Normalized share across these five names; attention is not quality.

Soligenix
31.4%
Aquestive Therapeutics
23.3%
Scynexis
21.7%
Janux Therapeutics
13.0%
Prelude Therapeutics
10.6%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Soligenix leads the conversation

It holds 31.4% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $0.00B.

Price path

Aquestive Therapeutics leads the available price paths

Its monthly-close return is +20.2% for the five-year window. At the other end, Soligenix is -99.9% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Scynexis has the widest latest margin

Its FY2025 net margin is -41.8%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Aquestive Therapeutics shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -9.2x while its five-year window price return is +20.2%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · SNGX

Soligenix

1,079available Prism news records

Prism top themes

Legal, arbitration & regulatory
37
Price action & investor response
19
Earnings & financial performance
11
Capital allocation & transactions
7

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+51.3%177 latest 12m vs 117 prior 12m
2024-01: 10 mentions2024-02: 5 mentions2024-03: 3 mentions2024-04: 13 mentions2024-05: 13 mentions2024-06: 3 mentions2024-07: 6 mentions2024-08: 5 mentions2024-09: 4 mentions2024-10: 18 mentions2024-11: 7 mentions2024-12: 5 mentions2025-01: 11 mentions2025-02: 35 mentions2025-03: 14 mentions2025-04: 5 mentions2025-05: 4 mentions2025-06: 3 mentions2025-07: 6 mentions2025-08: 15 mentions2025-09: 11 mentions2025-10: 6 mentions2025-11: 5 mentions2025-12: 14 mentions2026-01: 16 mentions2026-02: 11 mentions2026-03: 42 mentions2026-04: 33 mentions2026-05: 16 mentions2026-06: 2 mentions2024-012026-06

Machine-classified coverage tone

96.5% positive-0.9 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

rare disease treatment 39t-cell lymphoma 33checkpoint inhibitors lymphoma 32rare disease clinical trials 31gene therapy rare diseases 25antibody-drug conjugates lymphoma 18vaccine formulation 14orphan drug exclusivity 14

Keyword tag occurrences in available Prism news records.

Coverage: 2010-02-17–2026-06-11 · trend and themes shown through 2026-06
Areas of research · AQST

Aquestive Therapeutics

803available Prism news records

Prism top themes

Legal, arbitration & regulatory
47
Price action & investor response
38
Capital allocation & transactions
16
Earnings & financial performance
12
Macro demand & rates
8

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+62.6%187 latest 12m vs 115 prior 12m
2023-12: 0 mentions2024-01: 3 mentions2024-02: 7 mentions2024-03: 35 mentions2024-04: 17 mentions2024-05: 16 mentions2024-06: 13 mentions2024-07: 8 mentions2024-08: 29 mentions2024-09: 7 mentions2024-10: 7 mentions2024-11: 5 mentions2024-12: 9 mentions2025-01: 6 mentions2025-02: 11 mentions2025-03: 6 mentions2025-04: 10 mentions2025-05: 4 mentions2025-06: 8 mentions2025-07: 4 mentions2025-08: 10 mentions2025-09: 15 mentions2025-10: 8 mentions2025-11: 22 mentions2025-12: 3 mentions2026-01: 29 mentions2026-02: 47 mentions2026-03: 13 mentions2026-04: 15 mentions2026-05: 13 mentions2023-122026-05

Machine-classified coverage tone

79.4% positive-14.7 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

pharmacoepidemiology 22stock price 15stock performance 13share price 10angel investors 8drug safety monitoring 7clinical protocol 7stock surge 6

Keyword tag occurrences in available Prism news records.

Coverage: 2010-11-29–2026-05-19 · trend and themes shown through 2026-05
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

SCYX

Scynexis

60 mentions
Stock and valuation
35
Products, pricing and logistics
6

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 60 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

PRLD

Prelude Therapeutics

through 2025-11-12
Company announcements 5Leadership changes 5Earnings releases 4Business contracts 1
  1. Earnings releases

    (UNAUDITED) Three Months Ended September 30, (in thousands, except share and per share data) 2025 2024 Revenue $ 6,500 $ 3,000 Operating expenses Research and development 21,708 29,457 General and administrative 5,210 7,919 Total operating expenses 26,918 37,376 Loss from operations (20,418 ) (34,376 ) Other income, net 693 2,105 Net loss $ (19,725 ) $ (32,271 ) Per share information: Net loss per share of common stock, basic and diluted $ (0.26 ) $ (0.43 )

  2. Company announcements

    JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a $25 million equity investment and $100 million if option is exercised

  3. Business contracts

    Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program, including Prelude’s library of preclinical candidates.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SCYX

Scynexis

through 2025-11-06
Business contracts 6Earnings releases 6Company announcements 5Listing / IPO 2Lawsuits 1
  1. Company announcements

    JERSEY CITY, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the third quarter ended September 30, 2025.

  2. Earnings releases

    SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines ... today reported financial results for the year ended December 31, 2024.

  3. Regulatory

    cleared by the U.S. FDA for vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SNGX

Soligenix

through 2026-01-23
Company announcements 4Earnings releases 4Business contracts 1Regulatory 1
  1. Business contracts

    We have entered into an At Market Issuance Sales Agreement (the “sales agreement”) with Rodman & Renshaw LLC (“Rodman” or the “sales agent”), dated January 23, 2026, relating to shares of our common stock, par value $0.001 per share, offered by this prospectus supplement and the accompanying prospectus.

  2. Earnings releases

    Soligenix, Inc. (NASDAQ:SNGX) shares shot up 73% to $2.1793 after the company reported better-than-expected second-quarter EPS and sales.

  3. Regulatory

    Soligenix Inc. is scratching its chin as it decides how to react to the U.S. FDA’s refusal to file letter regarding Hybryte (synthetic hypericin) for treating early stage cutaneous T-cell lymphoma.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

AQST

Aquestive Therapeutics

through 2026-04-24
Earnings releases 17Company announcements 8Leadership changes 2Listing / IPO 2Business contracts 1
  1. Lawsuits

    According to the complaint filed in the U.S. District Court for the District of New Jersey the plaintiff alleges on behalf of purchasers of Aquestive Therapeutics, Inc. common shares between June 16, 2025 and January 8, 2026 that the defendants violated Federal Securities Laws.

  2. Regulatory

    after the company announced the receipt of a CRL for Anaphylm and a planned resubmission in Q3.

  3. Earnings releases

    Third Quarter 2025 Financials: Excluding the impact of one‑time recognition of deferred revenue in the third quarter of 2024, total revenues increased by $0.5 million, or 4% year over year to $12.8 million in the third quarter 2025.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

JANX

Janux Therapeutics

through 2026-02-05
Leadership changes 2Listing / IPO 2
  1. Leadership changes

    Janux Therapeutics announced chief medical officer Zachariah McIver, DO, PhD is leaving the company to pursue other opportunities.

  2. Listing / IPO

    Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that it has commenced an underwritten public offering of $300.0 million of shares of its common stock or, in lieu of common stock issued to certain investors that so choose, pre-funded warrants to purchase shares of its common stock.

  3. Leadership changes

    Janux Therapeutics named William Go, MD, PhD as chief medical officer, effective January 26.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence
2011 extracted base$66.70B
2016 extracted forecast$42.00B–$70.00B
Implied source CAGR9.5%
Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records
Latest 12m volume+3.4%24052 vs 23272 records
Positive classified tone65.3%+6.0 pp vs prior four quarters
2024-01: 2,385 mentions2024-02: 1,423 mentions2024-03: 1,374 mentions2024-04: 1,289 mentions2024-05: 1,487 mentions2024-06: 1,819 mentions2024-07: 1,355 mentions2024-08: 1,609 mentions2024-09: 1,720 mentions2024-10: 1,625 mentions2024-11: 1,853 mentions2024-12: 1,522 mentions2025-01: 2,799 mentions2025-02: 2,971 mentions2025-03: 2,174 mentions2025-04: 2,142 mentions2025-05: 1,683 mentions2025-06: 1,142 mentions2025-07: 1,921 mentions2025-08: 3,922 mentions2025-09: 2,081 mentions2025-10: 1,648 mentions2025-11: 1,720 mentions2025-12: 1,496 mentions2026-01: 1,701 mentions2026-02: 3,364 mentions2026-03: 1,972 mentions2026-04: 2,867 mentions2026-05: 218 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies
6,223
snowstorm and blizzard alerts
6,121
pharmaceutical marketing and sales strategies
6,014
winter weather preparedness
5,925
generic drug development and market trends
3,700
healthcare economics and market access
3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 101–108. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions
Comparisons
Anomalies

Prelude Therapeutics has the widest attention-readiness rank gap

It ranks #5 by measured news attention (10.6%) and #1 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Prelude Therapeutics in Companies Radar

Janux Therapeutics shows a price-operating divergence to inspect

Its displayed filing-revenue change is +175.0% while its available monthly-close return is -12.7%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Janux Therapeutics in Companies Radar
Explanations

Attention measures coverage volume, not quality

Soligenix's 31.4% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Soligenix in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Prelude Therapeutics's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 42/100 score.

Open Prelude Therapeutics in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon